An Open-label, Randomized, Phase 3 Study of MK-6482 in Combination with Lenvatinib (MK-7902) vs Cabozantinib for Second-line or Third-line Treatment in Participants with Advanced Renal Cell Carcinoma Who Have Progressed After Prior Anti PD-1/L1 Therapy
Principal investigator: Katriina Peltola
Trial site: HUS Comprehensive Cancer Center
